LOGIN
AAOS2017: Assessing major wound complication rate of rivaroxaban, LMWH or placebo in THA
April 2017
AAOS2017: Assessing major wound complication rate of rivaroxaban, LMWH or placebo in THA
Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A
A Prospective Randomized Study Comparing Oral Direct Factor Xa Inhibitor with Lowmolecular- weight Heparin for Evaluation of Surgical Wound Complications Following Total Hip Arthroplasty
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
Synopsis
958 patients scheduled for total hip arthroplasty were randomized to different groups for thromboprophylaxis. In patients <60 years of age (n=600), randomization was to either rivaroxaban, enoxaparin, or placebo. In patients 60 years of age or older (n=358), randomization was to either rivaroxaban or enoxaparin. The purpose of this study was to determine if there were any significant differences b...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.